Dr. Eric A. Klein, Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic, discusses prostate cancer research released at the American Urological Association (AUA) 2020 meeting demonstrating the positive impact of the Oncotype DX Genomic Prostate Score® (GPS™) test to help make treatment decisions in African-American men with clinically localized prostate cancer. He was also author on the abstract titled “A 17-Gene Genomic Assay as a Predictor of Outcomes in African Americans with Prostate Cancer” presented at AUA.
Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis, and kidney. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America. Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic.Dr. Klein received his medical degree from the University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.